L'élaboration d'un essai thérapeutiqueBIOLLAZ, J.Médecine et hygiène. 1991, Vol 49, Num 1875, pp 458-464, issn 0025-6749, 4 p.Article

INHIBITEURS DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINEBIOLLAZ J; BRUNNER HR.1982; CONCOURS MED.; ISSN 0010-5309; FRA; DA. 1982; VOL. 104; NO 8; PP. 1155-1168; 8 P.; BIBL. 46 REF.Article

De la liberté de prescription = A liberty to prescribeBIOLLAZ, J; BUCLIN, T.Médecine et hygiène. 1995, Vol 53, Num 2068, pp 872-874, issn 0025-6749Article

Les errances de la posologie = Wandering of drug dosageBIOLLAZ, J; BUCLIN, T.Médecine et hygiène. 1994, Vol 52, Num 2022, pp 881-886, issn 0025-6749, 5 p.Article

High-performance liquid chromatographic assay with fluorometric detection for flecainide and its major metabolites in urine and serumMUNAFO, A; BIOLLAZ, J.Journal of chromatography. 1989, Vol 490, Num 2, pp 450-457, issn 0021-9673Article

ESCAPE FROM MINERALOCORTICOID EXCESS: THE ROLE OF ANGIOTENSIN IIBIOLLAZ J; DUERR J; BRUNNER HR et al.1982; JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM; ISSN 0021-972X; USA; DA. 1982; VOL. 54; NO 6; PP. 1187-1193; BIBL. 34 REF.Article

Quelques aspects pharmacocinétiques et pharmacodynamiques de l'utilisation des antibiotiques chez la personne agée = Pharmacokinetics and pharmacodynamics of antibiotics in elderlyCOMETTA, A; BIOLLAZ, J.Médecine et hygiène. 1997, Vol 55, Num 2161, pp 887-890, issn 0025-6749Article

Troubles électrolytiques d'origine médicamenteuse: aspects physiologiques et physiopathologiques = Drug-induced electrolytic disorders: Physiologic and pathophysiologic studiesSTEINHAUSLIN, F; BIOLLAZ, J.Médecine et hygiène. 1989, Vol 47, Num 1791, pp 1202-1213, issn 0025-6749, 7 p.Article

DTC : nouvel essor pour un ancien dopant : Thérapeutique = DTC: new achievements for an old doping agentBUCLIN, T; BIOLLAZ, J.Médecine et hygiène. 2004, Vol 62, Num 2476, pp 677-681, issn 0025-6749, 5 p.Article

Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapyBURNIER, M; BIOLLAZ, J.Clinical pharmacokinetics. 1992, Vol 22, Num 5, pp 375-384, issn 0312-5963Article

ANTIHYPERTENSIVE THERAPY WITH MK 421: ANGIOTENSIN II-RENIN RELATIONSHIPS TO EVALUATE EFFICACY OF CONVERTING ENZYME BLOCKADEBIOLLAZ J; BRUNNER HR; GAVRAS I et al.1982; JOURNAL OF CARDIOVASCULAR PHARMACOLOGY; ISSN 0160-2446; USA; DA. 1982; VOL. 4; NO 6; PP. 966-972; BIBL. 31 REF.Article

FACTEURS AGGRAVANT L'ANEMIE EN HEMODIALYSE CHRONIQUE: DESTRUCTION EXAGEREE OU PERTES.WAUTERS JP; BIOLLAZ J; DELALOYE BISCHOF A et al.1980; SCHWEIZ. MED. WOCHENSCH.; ISSN 0036-7672; CHE; DA. 1980; VOL. 110; NO 49; PP. 1888-1890; ABS. ENG; BIBL. 10 REF.Article

ENALAPRL MALEATE AND A LYSINE ANALOGUE (MK-521): DISPOSITION IN MANULM EH; HICHENS M; GOMEZ HJ et al.1982; BR. J. CLIN. PHARMACOL.; ISSN 0306-5251; GBR; DA. 1982; VOL. 14; NO 3; PP. 357-362; BIBL. 15 REF.Article

ENALAPRIL MALEATE AND A LYSINE ANALOGUE (MK-521) IN NORMAL VOLUNTEERS; RELATIONSHIP BETWEEN PLASMA DRUG LEVELS AND THE RENIN ANGIOTENSIN SYSTEMBIOLLAZ J; SCHELLING JL; DES COMBES BJ et al.1982; BR. J. CLIN. PHARMACOL.; ISSN 0306-5251; GBR; DA. 1982; VOL. 14; NO 3; PP. 363-368; BIBL. 11 REF.Article

THREE NEW LONG-ACTING CONVERTING-ENZYME INHIBITORS: RELATIONSHIP BETWEEN PLASMA CONVERTING-ENZYME ACTIVITY AND RESPONSE TO ANGIOTENSINBIOLLAZ J; BURNIER M; TURINI GA et al.1981; CLIN. PHARMACOL. THER.; ISSN 0009-9236; USA; DA. 1981; VOL. 29; NO 5; PP. 665-670; BIBL. 15 REF.Article

THE RENAL EFFECTS OF CLONIDINE IN UNANESTHETIZED RATSBIOLLAZ J; ROCH RAMEL F; KIRCHERTZ EJ et al.1979; EUROP. J. PHARMACOL.; NLD; DA. 1979; VOL. 58; NO 4; PP. 407-418; BIBL. 2 P.Article

EFFECT OF A NEW ANGIOTENSIN CONVERTING ENZYME INHIBITOR MK 421 AND ITS LYSINE ANALOGUE ON THE COMPONENTS OF THE RENIN SYSTEM IN HEALTHY SUBJECTSBRUNNER DB; DESPONDS G; BIOLLAZ J et al.1981; BR. J. CLIN. PHARMACOL.; ISSN 0306-5251; GBR; DA. 1981; VOL. 11; NO 5; PP. 461-467; BIBL. 13 REF.Article

ANTIHYPERTENSIVE EFFECT OF THE NEW ORAL ANGIOTENSIN CONVERTING ENZYME INHIBITOR "MK-421"GAVRAS H; WAEBER B; GAVRAS I et al.1981; LANCET (BR. ED.); ISSN 0140-6736; GBR; DA. 1981; NO 8246; PP. 543-546; BIBL. 26 REF.Article

Pharmacovigilance : Nouveautés en médecine 2007 (Deuxième partie) = Pharmacovigilance UpdateLIVIO, F; BUCLIN, T; BIOLLAZ, J et al.Revue médicale suisse. 2008, Vol 4, Num 140, pp 150-154, issn 1660-9379, 5 p.Article

Prostaglandines et AINS : indications et risques dans la grossesse : Thérapeutique = Prostaglandins and NSAIDSs : Indications and risks during pregnancyROUSSO, P; BUCLIN, T; BIOLLAZ, J et al.Médecine et hygiène. 2001, Vol 59, Num 2342, pp 845-849, issn 0025-6749, 4 p.Article

Praticiens et prescription médicamenteuse économique = Practitioners and economical drug prescriptionBUCLIN, T; WASSERFALLEN, J.-B; BIOLLAZ, J et al.Médecine et hygiène. 1998, Vol 56, Num 2204, pp 758-765, issn 0025-6749, 7 p.Article

Cimetidine inhibition of ethmozine metabolismBIOLLAZ, J; SHAHEEN, O; WOOD, A. J. J et al.Clinical pharmacology and therapeutics. 1985, Vol 37, Num 6, pp 665-668, issn 0009-9236Article

Pharmacovigilance Update : Nouveautés en médecine 2009: deuxième partie = Pharmacovigilance UpdateLIVIO, F; BIOLLAZ, J; ROTHUIZEN, L et al.Revue médicale suisse. 2010, Vol 6, Num 232, pp 128-131, issn 1660-9379, 4 p.Article

Grossesse et vaccinations = Immunisation during pregnancyCSAJKA, C; ROUSSO, P; GYSLING, E et al.Médecine et hygiène. 1999, Vol 57, Num 2251, pp 809-811, issn 0025-6749Article

Méningite aseptique sur Salazopyrine : une observation et revue de la littérature = Aseptic meningitis as a side effect of sulfasalazineGERSTER, J. C; SCHERRER, U; BIOLLAZ, J et al.Rhumatologie (Aix-les-Bains). 1998, Vol 50, Num 6, pp 176-178, issn 0249-7581Article